TM9SF4 expression in tumor tissues: a novel diagnostic biomarker for gastrointestinal tumors
Rattachement africain : ee, lv, it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: The identification of novel biomarkers for the early detection and monitoring of gastric (GC) and colorectal cancer (CRC) is of paramount importance. TM9SF4 is a newly described V-ATPase interacting protein involved in the malignant progression of cancer cells. While TM9SF4 expression pattern and cellular localization have been described in in vitro in tumor cell lines of different histotypes, its expression in gastrointestinal tumor tissues has never been investigated. Methods: In this study, we detected by immunohistochemistry (IHC) in tumor and surrounding healthy tissues TM9SF4, in comparison with clinically adopted biomarkers CEA and CA 19-9 to evaluate TM9SF4 potential as a novel tissue marker for early detection and monitoring of GC and CRC cancers. Results: The expression of TM9SF4, CEA and CA 19-9 was evaluated in samples from 108 cancer patients (68 with GC and 40 CRC) and in healthy tissues from 20 non-cancer patients. Our results clearly suggest that TM9SF4 expression was significantly increased in GC and CRC samples and significantly correlated to disease stage in both cancer types. Conclusions: We propose TM9SF4 as highly specific cancer biomarker, exploitable for disease detection and staging of gastrointestinal cancers patients, with tumor tissue levels of expression outperforming those of clinically adopted markers such as CEA and CA 19-9.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- TM9SF4 expression in tumor tissues: a novel diagnostic biomarker for gastrointestinal tumors
- Date Crossref
- 01/11/2020
- Éditeur
- AME Publishing Company
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
HansaBioMed (Estonia) pays non établi dans la noticeEntreprise
-
Riga East University Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Latvia Institute of Clinical and Preventive Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Istituto Superiore di Sanità pays non établi dans la noticeOrganisme public
-
HansaBioMed Life Sciences LTD pays non établi dans la noticeEntreprise
-
Exosomics SpA pays non établi dans la noticeInstitution
-
Academic Histology Laboratory pays non établi dans la noticeStructure de recherche
HansaBioMed (Estonia), Riga East University Hospital et Institute of Clinical and Preventive Medicine — University of Latvia, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.